Walleye Capital LLC Bluebird Bio, Inc. Transaction History

Walleye Capital LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$0.85 - $1.26 $381,920 - $566,140	-449,318 Reduced 57.35%	334,118 $327,000
Q1 2024 May 15, 2024	BUY	$0.91 - $1.75 $712,926 - $1.37 Million	783,436 New	783,436 $1 Million
Q2 2023 Aug 14, 2023	BUY	$2.79 - $5.03 $2.33 Million - $4.21 Million	836,760 New	836,760 $2.75 Million
Q3 2022 Nov 14, 2022	BUY	$3.75 - $7.39 $237,360 - $467,757	63,296 New	63,296 $401,000
Q2 2022 Aug 08, 2022	SELL	$2.94 - $5.23 $381,403 - $678,482	-129,729 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$4.07 - $10.6 $486,926 - $1.27 Million	119,638 Added 1185.59%	129,729 $629,000
Q4 2021 Mar 03, 2022	SELL	$8.96 - $16.31 $252,277 - $459,224	-28,156 Reduced 73.62%	10,091 $100,000
Q3 2021 Nov 15, 2021	BUY	$11.24 - $21.0 $334,446 - $624,855	29,755 Added 350.39%	38,247 $731,000
Q2 2021 Aug 16, 2021	BUY	$18.04 - $22.09 $87,043 - $106,584	4,825 Added 131.58%	8,492 $272,000
Q3 2019 Nov 14, 2019	BUY	$59.47 - $93.1 $218,076 - $341,397	3,667 New	3,667 $337,000

151

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $27M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.